Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

Stock futures are quiet this morning, following a busy week that brought in a new President elect, a subsequent market rally, and an interest rate cut from the Federal Reserve. The Dow Jones ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

Market Reaction: Big Pharma's vaccine names dipped on Wednesday with Moderna, Inc. (NASDAQ:MRNA) ending the day down 2.78%, ...

Meanwhile, among the sector's biggest decliners were hospital operators, with HCA Healthcare Inc.'s stock (HCA) shedding 4.6%, Universal Health Services Inc. shares (UHS) falling 3.7% and shares of ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $150.00.

On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...

German biotech BioNTech saw its shares rise more than 3% to $114.98 pre-market today, as it reported financial results for the three months ended September 30, 2024, that beat expectations. Revenues ...